Suppr超能文献

针对人类主要组织相容性复合体产物的抗体可抑制I型和II型Fcγ受体。

Antibodies to human major histocompatibility complex products inhibit Fc gamma receptors types I and II.

作者信息

Neppert J, Jungi T W

机构信息

Institute of Transfusion Medicine, University of Kiel, Germany.

出版信息

Transfus Med. 1996 Jun;6(2):125-31. doi: 10.1046/j.1365-3148.1996.d01-61.x.

Abstract

We have analysed the effect of polyclonal and monoclonal antibodies of distinct IgG isotypes directed against products of the human major histocompatibility complex (MHC) on the function of Fc gamma receptors types I (Fc gamma RI) and II (Fc gamma RII). Human anti-D sensitized red blood cells (RBC), selectively binding to Fc gamma RI, and bovine or murine IgG1 (bIgG1 or mIgG1) sensitized RBC, selectively binding to Fc gamma RII, were employed as targets for the effector cell in order to distinguish the inhibition of both types. Using these targets it could be shown that human antibodies to products of the human MHC or murine monoclonal antibodies with the same specificity and mIgG2a isotype inhibited both the Fc gamma RI-and the Fc gamma RII-mediated function. In contrast, murine monoclonal antibodies with the same specificity but of the mIgG1 isotype only inhibited the Fc gamma RII-mediated function. In a control experiment, human and murine antibodies to products of the MHC did not impair the Fc gamma R-independent phagocytosis of Saccharomyces by monocytes and neutrophils. The present study suggests that this mechanism involves at least two different Fc gamma receptors.

摘要

我们分析了针对人类主要组织相容性复合体(MHC)产物的不同IgG同种型的多克隆和单克隆抗体对I型Fcγ受体(FcγRI)和II型Fcγ受体(FcγRII)功能的影响。人抗-D致敏红细胞(RBC)选择性结合FcγRI,牛或鼠IgG1(bIgG1或mIgG1)致敏红细胞选择性结合FcγRII,将其用作效应细胞的靶标以区分对两种类型的抑制作用。使用这些靶标可以表明,针对人类MHC产物的人抗体或具有相同特异性和mIgG2a同种型的鼠单克隆抗体抑制了FcγRI和FcγRII介导的功能。相比之下,具有相同特异性但为mIgG1同种型的鼠单克隆抗体仅抑制FcγRII介导的功能。在对照实验中,针对MHC产物的人抗体和鼠抗体不会损害单核细胞和中性粒细胞对酿酒酵母的不依赖FcγR的吞噬作用。本研究表明,该机制至少涉及两种不同的Fcγ受体。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验